Drug Shortage Report for TEVETEN PLUS
Report ID | 125760 |
Drug Identification Number | 02253631 |
Brand name | TEVETEN PLUS |
Common or Proper name | EPROSARTAN HYDROCHLOROTHIAZIDE |
Company Name | BGP PHARMA ULC |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | EPROSARTAN HYDROCHLOROTHIAZIDE |
Strength(s) | 600MG 12.5MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 3x10 |
ATC code | C09DA |
ATC description | ANGIOTENSIN II ANTAGONISTS, COMBINATIONS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2020-10-27 |
Actual start date | |
Estimated end date | 2020-11-03 |
Actual end date | 2020-11-02 |
Shortage status | Resolved |
Updated date | 2020-11-03 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 85 ADVANCE ROAD ETOBICOKE, ONTARIO CANADA M8Z 2S6 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v12 | 2020-11-03 | French | Compare |
v11 | 2020-11-03 | English | Compare |
v10 | 2020-10-28 | French | Compare |
v9 | 2020-10-28 | English | Compare |
v8 | 2020-10-24 | English | Compare |
v7 | 2020-10-20 | French | Compare |
v6 | 2020-10-20 | English | Compare |
v5 | 2020-10-15 | English | Compare |
v4 | 2020-10-14 | French | Compare |
v3 | 2020-10-14 | English | Compare |
v2 | 2020-10-06 | French | Compare |
v1 | 2020-10-06 | English | Compare |
Showing 1 to 12 of 12